Athersys Stock Quote ATHX Stock Price, News, Charts, Message Board, Trades

One share of ATHX stock can currently be purchased for approximately $1.41. The P/E ratio of Athersys is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. In the past three months, Athersys insiders have not sold or bought any company stock. MarketBeat has tracked 3 news articles for Athersys this week, compared to 2 articles on an average week. Has decreased from 27% to 16% over the past year, but is still higher than 75% of US stocks.

The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. After 13 years, the Food and Drug Administration has opened the door to fat profits for astute investors from fat pills. Only 1 people have added Athersys to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

• Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions.
• Their ATHX share price forecasts range from $5.50 to $6.25.
• Historical and current end-of-day data provided by FACTSET.
• Alliance Global Partners initiated coverage on Athersys in a research note on Monday, March 6th.
• After 13 years, the Food and Drug Administration has opened the door to fat profits for astute investors from fat pills.

Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage mahifx review is mahifx a scam or legit forex broker of its current stock price. Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Athersys: Subgroup Analysis As A Masterstroke

Our calculations are based on comprehensive, delayed quotes. Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares https://day-trading.info/ available to trade. AMAG Pharmaceuticals Inc. shares fell in afternoon trading Thursday, the day after the company issued an earnings report that fell shy of Wall Street expectations. Real-time analyst ratings, insider transactions, earnings data, and more. According to analysts’ consensus price target of $5.88, Athersys has a forecasted upside of 348.5% from its current price of $1.31.

There may be delays, omissions, or inaccuracies in the Information. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

Athersys Provides MultiStem Clinical Update

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

AIG, Google and Jabil are all making notable moves in the U.S. stock market today. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023. Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat’s FREE daily newsletter.

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH. StockNews.com initiated coverage on Athersys in a research note on Thursday. Alliance Global Partners initiated coverage on Athersys in a research note on Monday, March 6th.

Athersys announces 1-for-25 reverse stock split

Only 8 people have searched for ATHX on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.

Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those … Shares of several stem-cell companies jumped Friday on reports that stem-cells were used to grow an artificial trachea to treat a patient stricken with advanced cancer.

ATHX underperformed the US Biotechs industry which returned -1% over the past year. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank.

65.0% of employees surveyed would recommend working at Athersys to a friend. Since then, ATHX shares have increased by 67.9% and is now trading at $1.41. Athersys has a short interest ratio (“days to cover”) of 3.5, which is generally considered an acceptable ratio of short interest to trading volume. The company’s average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Is Athersys (NASDAQ:ATHX) In A Good Position To Invest In Growth?

A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Intraday Data provided by FACTSET and subject to terms of use.

Athersys has only been the subject of 1 research reports in the past 90 days. Quotes displayed in real-time or delayed by at least 15 minutes. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.

A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares. Money Flow Uptick/Downtick RatioMoney flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades.

Stock Activity

BOSTON — Shares of many of the publicly-traded stem cell researchers lost ground Tuesday, the day after a federal judge blocked a recent government decision to expand federal funding for certain types of embr… BOSTON — A federal judge on Wednesday upheld the Obama Administration’s decision to restore federal funding for certain types of embryonic stem-cell research, according to reports. Shares of Athersys reverse split before market open on Monday, August 29th 2022.

A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATHX, but not buy additional shares or sell existing shares. Athersys saw a drop in short interest during the month of February. As of February 28th, there was short interest totaling 1,140,000 shares, a drop of 8.1% from the February 13th total of 1,240,000 shares. Based on an average daily trading volume, of 321,200 shares, the days-to-cover ratio is presently 3.5 days.

Quotes & News

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Shares of stem-cell researchers regain ground, after being pushed down earlier in the week on investor concerns that a court ruling against the federal funding of embryonic stem-cell research would negatively impact the fl… BOSTON — A federal appeals court on Thursday ruled that federal funding of embryonic stem-cell research projects will continue while a recent judge’s ruling against such funding is under appeal, according to…